Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo

Paul Emery¹, Jiří Vencovský², Jeehoon Ghil³, Soo Yeon Cheong³, Young Hee Rho³

Affiliations

¹ Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
² Institute of Rheumatology, Prague, Czech Republic.
³ Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.

PMID: 27502892
DOI: 10.1136/annrheumdis-2016-210127

Free article

Comment

Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo

Paul Emery et al. Ann Rheum Dis. 2016 Oct.

Free article

. 2016 Oct;75(10):e65.

doi: 10.1136/annrheumdis-2016-210127. Epub 2016 Aug 8.

Authors

Paul Emery¹, Jiří Vencovský², Jeehoon Ghil³, Soo Yeon Cheong³, Young Hee Rho³

Affiliations

¹ Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
² Institute of Rheumatology, Prague, Czech Republic.
³ Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.

PMID: 27502892
DOI: 10.1136/annrheumdis-2016-210127

No abstract available

Keywords: Disease Activity; Infections; Treatment.

PubMed Disclaimer

Comment on

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.
Emery P, Vencovský J, Sylwestrzak A, Leszczyński P, Porawska W, Baranauskaite A, Tseluyko V, Zhdan VM, Stasiuk B, Milasiene R, Barrera Rodriguez AA, Cheong SY, Ghil J. Emery P, et al. Ann Rheum Dis. 2017 Jan;76(1):51-57. doi: 10.1136/annrheumdis-2015-207588. Epub 2015 Jul 6. Ann Rheum Dis. 2017. PMID: 26150601 Free PMC article. Clinical Trial.
Difference between Enbrel and Benepali treatment groups in 'hepatobiliary disorders'.
Scheinberg M, Azevedo V. Scheinberg M, et al. Ann Rheum Dis. 2016 Oct;75(10):e64. doi: 10.1136/annrheumdis-2016-210101. Epub 2016 Jul 18. Ann Rheum Dis. 2016. PMID: 27432354 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo

Affiliations

Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo

Authors

Affiliations

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical